Compare NWBI & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWBI | FTRE |
|---|---|---|
| Founded | 1896 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | NWBI | FTRE |
|---|---|---|
| Price | $13.01 | $17.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $14.00 | ★ $15.56 |
| AVG Volume (30 Days) | 753.7K | ★ 1.3M |
| Earning Date | 01-26-2026 | 03-02-2026 |
| Dividend Yield | ★ 6.19% | N/A |
| EPS Growth | ★ 13.78 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | $564,562,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $7.94 | $3.17 |
| Revenue Next Year | $8.90 | $0.07 |
| P/E Ratio | $14.96 | ★ N/A |
| Revenue Growth | ★ 15.71 | 1.88 |
| 52 Week Low | $10.75 | $3.97 |
| 52 Week High | $13.62 | $19.00 |
| Indicator | NWBI | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 66.94 | 58.86 |
| Support Level | $12.13 | $15.37 |
| Resistance Level | $12.46 | $17.24 |
| Average True Range (ATR) | 0.29 | 1.20 |
| MACD | 0.08 | -0.21 |
| Stochastic Oscillator | 95.94 | 70.91 |
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.